The Medicines and Healthcare products Regulatory Agency (MHRA)
has today, 12 June 2026, approved a new lower
dose version of the adrenaline (epinephrine) nasal spray,
EURneffy, for the emergency treatment of serious allergic
reactions (anaphylaxis) in children aged four
years and over.
This approval means younger children are eligible for a
needle-free treatment option for the first time in
the UK.
The 1 mg dose nasal spray
is indicated for children aged 4 years and over who
weigh between 15 kg and 30 kg. This extends access
beyond the previously authorised 2 mg product, which is intended
for adults and children 10 years and
above weighing 30 kg or more.
Adrenaline is a well-established treatment
for serious allergic reactions and is intended for
immediate self-administration at the first signs of
anaphylaxis, before emergency medical help
arrives.
The nasal spray delivers a dose
into the nostril and is suitable for use even
if the nose is congested. As with adrenaline
auto-injectors, two doses (sprays) must always be
carried in case a second dose is needed before the ambulance
arrives. 999' must be
dialled immediately after a dose has been
given.
The new 1 mg dose provides an alternative for
younger patients, who until now have relied on injectable
adrenaline devices.
As with any medicine, the MHRA will keep the safety and
effectiveness of the adrenaline nasal spray under close
review.
Notes to editors
